文献速递肝病

在基于替诺福韦的治疗结束前超过3个月换用恩替卡韦可能减少乙肝e抗原阴性患者的早期复发和肝炎发作

Switching to Entecavir >3 Months Before the End of Tenofovir-Based Therapy in Hepatitis B e Antigen-Negative Patients May Reduce Early Relapse and Hepatitis Flare.
PubMed 文献 · Am J Gastroenterol · 2025-07-02

这项回顾性队列研究纳入18例乙肝e抗原阴性患者,在终止治疗前至少12周将替诺福韦二吡呋酯或替诺福韦艾拉酚胺换为恩替卡韦,并与两组各1:2匹配的对照组比较。换药组24周临床复发率和肝炎发作率均低于替诺福韦对照组,与恩替卡韦对照组差异无统计学意义。作者认为该换药策略可能减少临床复发和肝炎发作,似乎对更安全地停止基于替诺福韦的治疗有临床价值。

要点

  • 替诺福韦换恩替卡韦组24周临床复发率16.7% vs 替诺福韦对照组58.3%(P=0.009)。
  • 换药组24周肝炎发作率11.1% vs 替诺福韦对照组50%(P=0.013)。
  • 换药组与恩替卡韦对照组的所有差异均无统计学意义。

核心结论

  • 结果证实临床复发的时间与终止治疗前最后使用的抗病毒药物相关。
  • 在终止治疗前至少12周换用恩替卡韦的策略可能减少24周内的临床复发、肝炎发作及肝炎发作的严重程度。
  • 该策略似乎对更安全地停止基于替诺福韦的治疗有临床用处和重要性。

研究设计与样本

  • 回顾性队列研究:18例乙肝e抗原阴性患者在终止治疗前至少12周将替诺福韦二吡呋酯或替诺福韦艾拉酚胺换为恩替卡韦。
  • 招募两组对照组,按年龄、性别、基因型、肝硬化、基线乙肝病毒DNA和定量乙肝表面抗原各1:2匹配。
  • 所有患者在终止治疗后每1-3个月随访至少6个月。

主要发现

  • 与替诺福韦/替诺福韦艾拉酚胺对照组相比,换药组第24周临床复发率更低(16.7% vs 58.3%;P=0.009)。
  • 与替诺福韦/替诺福韦艾拉酚胺对照组相比,换药组第24周肝炎发作率更低(11.1% vs 50%;P=0.013)。
  • 丙氨酸氨基转移酶超过正常上限10倍的肝炎发作率也低于替诺福韦/替诺福韦艾拉酚胺对照组(5.6% vs 33.3%;P=0.040)。
  • 与恩替卡韦对照组相比的所有差异均无统计学意义。

临床怎么用

  • 作者认为,在终止治疗前至少12周换用恩替卡韦的策略可能减少临床复发和肝炎发作,似乎对更安全地停止基于替诺福韦的治疗有临床用处和重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Studies have shown that off-therapy clinical relapses occur much more frequently within 24 weeks and seems more severe in tenofovir disoproxil fumarate (TDF)-treated than in entecavir (ETV)-treated patients. A small retrospective study reported a significantly lower 24-week clinical relapse rate in 40 non-ETV (including 3 TDF)-treated patients after switching to ETV for ≥12 weeks before the end of therapy (EOT). To confirm the effect of the ETV-switching strategy, a retrospective cohort study was conducted. METHODS: TDF or tenofovir alafenamide (TAF) treatment in 18 hepatitis B e antigen-negative patients was switched to ETV for ≥12 weeks before EOT. Two control groups each 1:2 matched in age, sex, genotype, cirrhosis, baseline hepatitis B virus DNA, and quantitative hepatitis B surface antigen were recruited. All patients were followed up every 1-3 months for ≥6 months after EOT. RESULTS: Compared with the TDF/TAF-control, the incidence of clinical relapse and hepatitis flare by week 24 was lower (16.7 vs 58.3%; P = 0.009; 11.1 vs 50%; P = 0.013, respectively). The rate of hepatitis flare with alanine aminotransferase >10 times upper limit of normal was also lower than the TDF/TAF-control group (5.6 vs 33.3%; P = 0.040). All differences compared with the ETV-control group were nonsignificant. DISCUSSION: The results confirm that the timing of clinical relapse is associated with the last antiviral agent used before EOT. Furthermore, the ETV-switching strategy may reduce clinical relapse and hepatitis flare and the severity of hepatitis flare within 24 weeks after EOT. This strategy seems clinically useful and important for a safer cessation of TDF-based treatment.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Chen YC, Jeng WJ, Chien RN, et al. Switching to Entecavir >3 Months Before the End of Tenofovir-Based Therapy in Hepatitis B e Antigen-Negative Patients May Reduce Early Relapse and Hepatitis Flare. Am J Gastroenterol. 2025. PMID: 40600959. doi:10.14309/ajg.0000000000003630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。